HBV Dna Level at 24 Weeks is the Best Predictor of Virological Response to Adefovir Add-On Therapy in Patients with Lamivudine Resistance

Abstract

Background

The aim of this study was to investigate the relationship between HBV DNA levels at baseline and on-treatment and the virological response at 96 weeks after adefovir add-on therapy in chronic hepatitis B (CHB) patients with lamivudine resistance.

Methods

Lamivudine and adefovir combination therapy was administered to 122 CHB patients for >24 months.

Results

Virological response (HBV DNA negativity) was achieved in 53 (43.3%) and 62 patients (50.8%) at 48 and 96 weeks, respectively. The receiver operating characteristic curve analysis showed that the HBV DNA level at week 24 had a greater power (area under the receiver operating characteristic curve 0.978; 95% CI 0.949, 1.000; P<0.001) to predict the virological response at week 96 of treatment than did the pre-treatment HBV DNA level (area under the receiver operating characteristic curve 0.771; 95% CI 0.640, 0.902; P<0.001). The best cutoff value for the HBV DNA level, at week 24, for the prediction of the virological response at week 96 was 200 IU/ ml (3 log₁₀ copies/ml), with a sensitivity and specificity of 90.3% and 95.0%, respectively. Using this time frame and cutoff value, 56 (90.3%) out of 62 patients that had a virological response at 96 weeks had <200 IU/ml HBV DNA at 24 weeks.

Conclusions

Although the HBV DNA level at baseline is often used to predict the antiviral potency of lamivudine and adefovir combination treatment in CHB patients with lamivudine resistance, the results of this study suggest that the HBV DNA level at 24 weeks is a better marker for the virological response.

References

Chen

C.J.

, Yang

H.I.

, Su

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65–73.

Iloeje

U.H.

, Yang

H.I.

, Su

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678–686.

Liaw

Y.F.

, Leung

N.W.

, Chang

T.T.

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172–180.

Lau

D.T.

, Khokhar

M.F.

, Doo

Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828–834.

Lok

A.S.

, Lai

C.L.

, Leung

Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714–1722.

Hadziyannis

S.J.

, Tassopoulos

N.C.

, Heathcote

E.J.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800–807.

Marcellin

, Chang

T.T.

, Lim

S.G.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808–816.

Peters

M.G.

, Hann Hw

, Martin

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91–101.

Perrillo

, Hann

H.W.

, Mutimer

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81–90.

10.

Fung

, Lai

C.L.

, Yuen

J.C.

Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir Ther 2007; 12: 41–46.

11.

Rapti

, Dimou

, Mitsoula

, Hadziyannis

S.J.

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307–313.

12.

Chen

C.H.

, Wang

J.H.

, Lee

C.M.

Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther 2006; 11: 771–778.

13.

Fung

S.K.

, Chae

H.B.

, Fontana

R.J.

Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283–290.

14.

Chan

H.L.

, Wong

V.W.

, Tse

C.H.

Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther 2007; 25: 891–898.

15.

Yatsuji

, Suzuki

, Sezaki

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up. J Hepatol 2008; 48: 923–931.

16.

Hosaka

, Suzuki

Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. J Gastroenterol 2007; 42: 368–374.

17.

Lampertico

, Vigano

, Manenti

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414–1419.

18.

Buti

, Elefsiniotis

, Jardi

Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol 2007; 47: 366–372.

19.

Yuen

M.F.

, Fong

D.Y.

, Wong

D.K.

Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007; 46: 1695–1703.

20.

Lai

C.L.

, Leung

, Teo

E.K.

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528–536.

21.

Chan

H.L.

, Heathcote

E.J.

, Marcellin

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147: 745–754.

22.

Gallego

, Sheldon

, Garcia-Samaniego

Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat 2008; 15: 392–398.

23.

Shin

J.W.

, Park

N.H.

, Jung

S.W.

Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients. Antivir Ther 2009; 14: 181–186.

24.

Kim

M.C.

, Jung

S.W.

, Shin

J.W.

, Park

N.H.

The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance. Dig Dis Sci 2011; 56: 1215–1221.

25.

Lampertico

, Vigano

, Manenti

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445–1451.

26.

Vassiliadis

, Nikolaidis

, Giouleme

Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2005; 21: 531–537.

27.

Kurashige

, Hiramatsu

, Ohkawa

Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. J Gastroenterol 2009; 44: 601–607.

28.

Berg

, Marcellin

, Zoulim

Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010; 139: 1207–1217.

29.

van Bömmel

, de Man

R.A.

, Wedemeyer

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73–80.

30.

Yuen

M.F.

, Sablon

, Hui

C.K.

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785–791.

31.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B. Hepatology 2007; 45: 507–539.

32.

Keeffe

E.B.

, Dieterich

D.T.

, Han

S.H.

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936–962.

33.

Kim

, Jee

Y.M.

, Song

B.C.

Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology 2007; 50: 52–57.